CervoMed is a clinical stage company targeting synaptic dysfunction to treat age-related neurologic disorders. The Company is currently developing neflamapimod, an oral small molecule brain penetrant specific p38 alpha kinase inhibitor. Positive clinical data with neflamapimod, including significant improvement (vs. placebo and baseline) on multiple cognitive and functional clinical endpoints, as well positive effects on EEG and biomarkers, from a 91-patient controlled 16-week phase 2a exploratory clinical study in Dementia with Lewy bodies (DLB) have been published. Neflamapimod is currently being evaluated in a Phase 2b study (named ReWinD-LB) in patients with DLB.. CervoMed was formed in August 2023 with completion of a reverse merger between EIP Pharma (then private) with Diffusion Pharmaceuticals. CervoMed expects to complete enrollment in RewinD-LB in the first half of 2024 and then report primary efficay results from the study in the second half of 2024.